Skip to content
Drug Regulatory Authority of Pakistan

Drug Regulatory Authority of Pakistan

Ministry of National Health Services, Regulations & Coordination

اردو |  English
  • facebook
  • twitter
  • envelope

Menu

  • About Us
    • DRAP at a Glance
    • Organization
    • Executive Management
    • Legislation
    • Boards and Committees
    • Quality Management System
  • Therapeutic Goods
    • Drugs
    • Medical Devices
    • Alternative Medicine
    • Controlled Substances
    • Emergency Use Authorizations
    • Clinical Trials Oversight
    • Licensing and Inspections
    • Quality Controls Labs
    • Import & Export
    • Advertisement Approvals
  • Safety Info
    • Product Recalls
    • Safety Communication
    • Safety Reporting
  • News & Updates
    • Regulatory Updates
    • Press Releases
    • Careers
    • Tenders
    • Events
  • Publications
    • Essential Medicine Lists
    • Guidelines
    • Newsletters
    • Regulatory Procedures
    • Regulatory Fees
    • Application Forms
    • Public Consultation
    • Minutes of the Meetings
  • E-Services
  • Medicine Availability
    • Public Medicine Shortage Reporting
    • Hospital Medicine Shortage Reporting
    • Focal Person Nomination
  • Support
    • Facilitation Desk
    • Complaints
    • Contact Us
Home > Safety Info > Safety Communication > Safety Alerts

Safety Alerts

Suspension of marketing authorisations of 17-Hydroxyprogesterone caproate (17- OHPC) due to its ineffectiveness in authorised uses

Abdul Qadir Safety Alerts July 9, 2025July 18, 2025SafetyAlert
58-Suspension-of-marketing-authorisations-of-17-OHPC-due-to-its-un-effectivenessDownload

Risk of Meningioma with Medroxyprogesterone Acetate.

Abdul Qadir Safety Alerts July 9, 2025July 9, 2025
59-Risk-of-meningioma-with-Medroxyprogesterone-AcetateDownload

Potential Risk of Tumour Lysis Syndrome with Sorafenib

Abdul Qadir Safety Alerts April 25, 2025July 18, 2025
57-Potential-Risk-of-Tumour-Lysis-Syndrome-with-SorafenibDownload

Safety Alert of Risk of persistent corneal injury and significant visual impairment with Chlorhexidine (cutaneous use)

Abdul Qadir Safety Alerts April 25, 2025July 18, 2025
56-Safety-Alert-of-Risk-of-persistent-corneal-with-ChlorhexidinDownload

Safety Alert of Risk of severe cutaneous adverse reactions with Cefotaxime

Abdul Qadir Safety Alerts April 7, 2025April 7, 2025
Safety-Alert-of-Risk-of-severe-cutaneous-adverse-reactions-with-CefotaximeDownload

Safety Alert risk of severe chemical irritation and damage to tissues with
Promethazine hydrochloride injection

Abdul Qadir Safety Alerts April 7, 2025April 7, 2025
Safety-Alert-risk-of-severe-chemical-irritation-and-damage-to-tissuesDownload

Safety Alert of Risk of Drug-Induced Liver Injury (DILI) and Severe Cutaneous
Adverse Reactions (SCARs) with Ezetimibe

Abdul Qadir Safety Alerts April 7, 2025April 7, 2025
Safety-Alert-of-Risk-of-Drug-Induced-Liver-Injury-DILI-and-Severe-CutaneousDownload

Safety Alert of Risk of pathological gambling with Aripiprazole

Abdul Qadir Safety Alerts April 7, 2025April 7, 2025
Safety-Alert-of-Risk-of-pathological-gambling-with-AripiprazoleDownload

Reports of serious adverse reactions with Ceftriaxone injection due to
unintentional mixing during reconstitution.

Abdul Qadir Safety Alerts March 24, 2025March 24, 2025
Advisory-on-reports-of-serious-adverse-reactions-with-Ceftriaxone-injection-due-to-unintentional-mixing-during-reconstituDownload

Safety Alert of Risk of Medication Errors resulting due to inadvertent intrathecal Tranexamic Acid Injection

Abdul Qadir Safety Alerts March 20, 2025May 14, 2025
51-2-Safety-alert-of-risk-of-medication-errors-resulting-due-to-inadvertent-intrathecal-tranexamicFDownload
  • ← Previous
  • Product Recalls
    • Recall Alerts
    • Therapeutic Products Recalls
    • Recalls and Rapid Alerts
  • Safety Communication
    • Safety Alerts
    • Pharmacovigilance Newsletter
    • Health Professional Alerts
  • Safety Reporting
    • How DRAP Monitor Safety
    • Adverse Events Reporting
    • Pharmacovigilance System
    • Product Quality Defects

Quick Navigation

Archives

Drug Regulatory Authority of Pakistan

  • Islamabad | Karachi | Lahore | Peshawar | Quetta
  • Phone: 0800-03727 (Mon to Fri 08:30AM to 04:30PM)
  • Website: www.dra.gov.pk
Developed by MIS Division. All rights reserved to Drug Regulatory Authority of Pakistan
  • Contact Us
  • Report a Problem